Price
$207.68-1.75%Social Signal Score
Analyst Ratings
25 analysts52-week range
- Last close
- $207.68
- Off 52w high
- -6.1%
- 200-day average
- $135.43
- vs 200-day
- +53.4%
Revenue
$197.56M+1809.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark A. Goldsmith
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 883
- Beta
- 1.43
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 9.22
Financials
Revenue
$197.56M+1809.3%Net Income
$-407.46MEBITDA
$-373.05MFree Cash Flow
$-419.35MEPS (diluted)
$-1.90Shares Outstanding (diluted)
214.95M+489.3%Operating Expenses
$570.38MCash & Debt
$3.65BReturn of Capital
$0.00Revenue by Segment (annual)
$35.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.13B | $-5.95 |
| 2024 | $0.00 | $-600.09M | $-3.58 |
| 2023 | $11.58M | $-436.37M | $-3.86 |
| 2022 | $35.38M | $-248.71M | $-3.08 |
| 2021 | $29.39M | $-187.09M | $-2.57 |
| 2020 | $42.98M | $-108.16M | $-1.62 |
| 2019 | $50.04M | $-47.66M | $-1.31 |
| 2018 | $20.16M | $-41.79M | $-1.15 |
| 2017 | $0.00 | $-31.13M | $-0.85 |
Valuation
RVMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+28.57%Social Signal Score
Mentions (94)
- News (RSS)fool·2d ago·Negative
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist? Rasonque is off to an impressive start. Here’s what that could mean for Revolution Medicines.
View source ↗ - News (RSS)guardian·2d ago·Positive
These US fishers see offshore wind as a ‘godsend’. Trump wants to shut it down Despite the president’s attacks, Sea Services is training New England fishers in offshore wind construction and providing them with a second income streamOn a rainy September morning, the Pamela Ann, a rusty, 86ft (26-metre) scallop boat, docked in New Bedford, Massachusetts. Its crew had spent the past 12 days at sea, recording mammal sightings, monitoring vessels to ensure they didn’t enter construction zones, and k
View source ↗ - Newsbenzinga.com·2d ago·Negative
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen Revolution Medicines, Inc. (NASDAQ:RVMD) on Thursday reported encouraging updated results from its Phase 1/2 RMC-GI-102 open-label study of Rasonque (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for metastatic pancreatic adenocarcinoma (PDAC).
View source ↗ - News (RSS)investing·2d ago·Neutral
Revolution Medicines reports updated pancreatic cancer trial data
View source ↗ - Newsglobenewswire.com·3d ago·Negative
… Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-pacl…
View source ↗ - Newszacks.com·5d ago·Neutral
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.
View source ↗ - 4chan /biz/biz·5d ago·Negative
The Economist | 2027 predictions 1. Global stock market crash. 2. The largest AI powered cyberattack in history. 3. Banking crisis and bank runs 4. China invades or blockades Taiwan. 5. Major escalation in the Middle East. 6. Global oil supply crisis. 7. AI bubble bursts, triggering a tech crash. 8. Massive blackouts across multiple countries. 9. Global financial system reset. 10. Marine Le Pen wins the French presidential election. 11. Revolution and mass protests in France. 12. Russia-NATO con
View source ↗ - 4chan /biz/biz·6d ago·Negative
…dous d****** like leveraged ETF's and yieldmaxx funds. for interesting insight into single stock movement i would recommend looking at the charts for APLD, GOOG and RVMD. if you want something that's supposedly not as tied to the S&P500 but still diversified, look into FMTM, SGRT, COPY, and ICPY, these four do not have my seal of approval however i cannot in good faith truly trash talk them, look into them for further insight on an introduction to meaningful diversification into stocks with wh…
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…b), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who h…
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)zerohedge·9d ago·Negative
Is Mamdani's Plan To Disband NYPD Riot Control-Unit A Gift To The 'Protest Industrial Complex' Is Mamdani's Plan To Disband NYPD Riot Control-Unit A Gift To The 'Protest Industrial Complex' Socialist New York City Mayor Zohran Mamdani's plan to dismantle the NYPD's roughly 600-officer protest unit could hand far-left activist networks, including NGOs linked to China-based Marxist financier Neville Roy Singham, a gift by weakening the city's ability to respond to large demonstrations or riots.JUS
View source ↗ - News (RSS)seekingalpha·10d ago·Positive
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
View source ↗ - 4chan /biz/biz·10d ago·Neutral
…dous d****** like leveraged ETF's and yieldmaxx funds. for interesting insight into single stock movement i would recommend looking at the charts for APLD, GOOG and RVMD. if you want something that's supposedly not as tied to the S&P500 but still diversified, look into FMTM, SGRT, COPY, and ICPY, these four do not have my seal of approval however i cannot in good faith truly trash talk them, look into them for further insight on an introduction to meaningful diversification into stocks with wh…
View source ↗ - 4chan /biz/biz·10d ago·Neutral
…ous d****** like leveraged ETF's and yieldmaxx funds. for interesting insight into single stock movement i would recommend looking at the charts for APLD, GOOG and RVMD. if you want something that's supposedly not as tied to the S&P500 but still diversified, look into FMTM, SGRT, COPY, and ICPY, these four do not have my seal of approval however i cannot in good faith truly trash talk them, look into them for further insight on an introduction to meaningful diversification into stocks with wh…
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO.
View source ↗ - News (RSS)fool·14d ago·Negative
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
View source ↗ - Newsfool.com·14d ago·Negative
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy? Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
View source ↗ - News (RSS)zerohedge·15d ago·Negative
"Dissatisfaction With Democracy": China Celebrates The Midterm Elections As Evidence That Democracy Is Dying In The West "Dissatisfaction With Democracy": China Celebrates The Midterm Elections As Evidence That Democracy Is Dying In The West Authored by Jonathan Turley,Winston Churchill once famously observed that "No one pretends that democracy is perfect or all-wise. Indeed, it has been said that democracy is the worst form of Government, except for all those other forms that have been tried f
View source ↗ - News (RSS)marketwatch·17d ago·Negative
This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time’ Revolution Medicines’ brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
View source ↗ - Newsseekingalpha.com·17d ago·Negative
…Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained commercial traction or pivotal readouts materialize. RASONQUE's clinical data show clear superiority over chemotherapy in pancreatic cancer; expansion into NSCLC and other solid tumors underpins RVMD's multi-asset pipeline thesis.
View source ↗ - Newszacks.com·17d ago·Positive
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake Revolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
Revolution Medicines rises on Q3 beats; maintains 2026 guidance
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Neutral
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $2.34. This compares to a loss of $1.61 per share a year ago.
View source ↗ - News (RSS)ft·23d ago·Neutral
Stockpickers: London Stock Exchange, Ultimate Products, Revolution Beauty Our experts discuss which companies to buy, sell or hold this week
View source ↗ - Newsprnewswire.com·23d ago·Neutral
Medicilon remet à Revolution Medicines le prix « Excellence en matière de partenariat client » /PRNewswire/ -- Le Dr Yang Liu, directeur de la chimie médicinale chez Revolution Medicines, Inc., et le Dr Kristof Pota, scientifique principal, ont visité le
View source ↗ - News (RSS)fool·24d ago·Positive
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution These aren’t top AI stocks, but the technology is helping improve their businesses.
View source ↗ - Newsfool.com·24d ago·Negative
Could Revolution Medicines Be a Millionaire-Maker Stock? Revolution Medicines' stock has soared over 9x in three years. This success has been driven by excitement about the company's cancer drug, Rasonque.
View source ↗ - News (RSS)fool·26d ago·Positive
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run? The biotech has experienced a pullback in recent weeks.
View source ↗ - Newsfool.com·26d ago·Positive
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run? Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines during the second quarter. The biotech earned approval for an innovative medicine for pancreatic cancer in the third quarter.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
Revolution Medicines to Participate in November 2026 Investor Conferences REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in two upcoming investor conferences.
View source ↗ - News (RSS)oilprice·29d ago·Neutral
Trump Targets $6.2 Billion Offshore Wind Project Nearing Completion United States President Donald Trump has repeatedly targeted offshore wind since coming into office last year, as he strives to expand the country’s fossil fuel sector and shift the focus away from renewable energy. Trump has sought to halt the development of several offshore wind projects and has even resorted to paying companies to relinquish their leases on areas off the U.S. coast to instead invest in oil and gas projects. N
View source ↗ - Newsglobenewswire.com·30d ago·Negative
…Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the European Society for Medical Onco…
View source ↗ - Newsglobenewswire.com·32d ago·Negative
…ial Results for Third Quarter 2026 After Market Close on November 4, 2026 REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m…
View source ↗ - News (RSS)zerohedge·33d ago·Neutral
The Great Rare Earth Disconnect: Prices Up 23%, Miners Down 28% The Great Rare Earth Disconnect: Prices Up 23%, Miners Down 28% Here is a question that should be harder to answer than it is: China still controls the rare earth spigot, the latest Trump-Xi summit did nothing to loosen its grip, Japan is about to run out of yttrium, Washington has put a $110/kg floor under NdPr, and Western buyers are paying anywhere from 5x to 346x the Chinese price for heavy rare earths. So why are rare earth sto
View source ↗ - News (RSS)zerohedge·33d ago·Neutral
As France Burns, Media Insists It's 'Mostly Peaceful'; Blames Right-Wing Influencers As France Burns, Media Insists It's 'Mostly Peaceful'; Blames Right-Wing Influencers Authored by Steve Watson via Modernity.news, France is burning. Historic buildings torched, thousands of shops looted, streets turned into war zones, firefighters attacked, and police overwhelmed. The official line from Macron's government, the BBC, and the rest of the compliant media is that this is about "education reform," te
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inh…
View source ↗ - 4chan /biz/biz·36d ago·Neutral
In the Shadow of Gold From DIE ZEIT, No. 48/1961 · November 24, 1961 Silver and the price of silver are making headlines By Melchior Palyi Page 1 For three generations, silver has occupied the poorhouse of the economy. Its retreat began in 1873, when Bismarck converted Germany's silver currency to the English-style gold standard, thereby throwing substantial quantities of monetary silver onto the market. The Netherlands, Austria, and the Scandinavian countries followed suit. In 1874, the free co
View source ↗ - Newsbenzinga.com·37d ago·Positive
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Revolution Medicines Inc. (NASDAQ:RVMD) has significant growth opportunities beyond pancreatic cancer, according to William Blair, which initiated coverage of the biotechnology company with an Outperform rating and a $226 price forecast.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
…inder project based on its potential to address a high unmet medical need REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of RASONQUE (daraxonrasib)…
View source ↗ - News (RSS)zerohedge·39d ago·Neutral
Futures Rise Ahead Of Hot CPI As Houthis Torch Aramco HQ, ASML Beat Fails To Revive Chip Trade Futures Rise Ahead Of Hot CPI As Houthis Torch Aramco HQ, ASML Beat Fails To Revive Chip Trade US futures are higher, with small caps leading and tech lagging, as traders brace for what is expected to be the hottest monthly CPI print since the spring, digest more escalation in the Gulf after Yemen's Houthis hit Saudi Aramco's Dhahran headquarters and vowed more strikes on Saudi airports and oil facilit
View source ↗ - Newsglobenewswire.com·48d ago·Negative
…onrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a …
View source ↗ - News (RSS)seekingalpha·50d ago·Neutral
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
View source ↗ - News (Marketaux)seekingalpha.com·50d ago·Neutral
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold (NASDAQ:RVMD) Revolution Medicines, [+144 characters]
View source ↗ - News (RSS)forbes·54d ago·Neutral
Why The EV Charging Revolution Needs Batteries That Never Move Could space-age battery technology unlock faster EV charging? EnerVenue’s stationary storage batteries could ease grid constraints and make renewable energy more useful.
View source ↗ - News (RSS)seekingalpha·55d ago·Positive
Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution
View source ↗ - Newsfool.com·59d ago·Neutral
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
View source ↗ - News (RSS)zerohedge·59d ago·Neutral
Mamdani Campaign Alum Living In China Talks US Revolution: "Very Surprised If There's No Violence Going Forward" Mamdani Campaign Alum Living In China Talks US Revolution: "Very Surprised If There's No Violence Going Forward" Explicit calls to overthrow capitalism only suggest revolutionary goals within the reformist socialist movement. There have been reports that some of these reformist socialists have coordinated with foreign subversion networks in Cuba and China or used NGOs to conduct hybri
View source ↗ - News (RSS)zerohedge·62d ago·Positive
Trump Announces 'AI Force', Plans To Name AI Czar As US Pushes Tech Dominance Trump Announces 'AI Force', Plans To Name AI Czar As US Pushes Tech Dominance Authored by AG News Staff via American Greatness, President Donald Trump announced plans to form an "AI Force" and appoint an artificial intelligence czar as his administration looks to promote the rapidly growing technology while using existing laws to address potential wrongdoing. Trump argued Democrats are attempting to create public doubt
View source ↗ - News (RSS)zerohedge·65d ago·Positive
Huge Parallel Pro-Iran Demonstrations Take Over Sanaa & Tehran Huge Parallel Pro-Iran Demonstrations Take Over Sanaa & Tehran Parallel protests were held in Tehran and Sanaa on Friday - both involving Shia populations expressing defiance at the US-Saudi-Israel axis, at a moment the region is on fire and Iran and its proxies seek to assert dominance and control over global energy transit chokepoints. All the while American bases and forces are largely in retreat, as even Pentagon internal finding
View source ↗ - News (RSS)fool·65d ago·Negative
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
View source ↗ - News (RSS)independent·66d ago·Negative
Revolution Beauty set for return to profit amid turnaround The group expects to report half-year underlying earnings of ‘not less than’ £2 million, following losses of £12.5 million a year earlier.
View source ↗ - News (RSS)standard·66d ago·Negative
Revolution Beauty set for return to profit amid turnaround The group expects to report half-year underlying earnings of ‘not less than’ £2 million, following losses of £12.5 million a year earlier.
View source ↗ - Newsfool.com·66d ago·Positive
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.
View source ↗ - 4chan /biz/biz·68d ago·Positive
>>62691401 We need a Revolution against (((tptb))) https://youtu.be/Lz4Vsd2oRuc?si Covfefe
View source ↗ - News (Marketaux)gurufocus.com·69d ago·Positive
RVMD Stock Rises on FDA Breakthrough Therapy Designation Amid High Price-to-Sales Valuation On September 14, 2026, Revolution</e[+258 characters]
View source ↗ - Newsglobenewswire.com·69d ago·Negative
…ombination with Chemotherapy for First Line Metastatic Pancreatic Cancer REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-sele…
View source ↗ - News (RSS)seekingalpha·78d ago·Neutral
Vertiv: The Backbone Of AI Revolution
View source ↗ - Newsmarketbeat.com·79d ago·Neutral
Revolution Medicines Got Its Breakthrough—What Moves It Next? Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
View source ↗ - Newszacks.com·79d ago·Neutral
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·81d ago·Negative
…cines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib…
View source ↗ - News (Marketaux)seekingalpha.com·82d ago·Positive
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) Revolution Medicines ([+191 characters]
View source ↗ - News (RSS)nyt·83d ago·Negative
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
View source ↗ - News (RSS)seekingalpha·83d ago·Positive
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
View source ↗ - News (RSS)seekingalpha·85d ago·Neutral
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
View source ↗ - News (RSS)thestreet·85d ago·Negative
Patients with the deadliest cancer finally have something that works The FDA just cleared a first-of-its-kind pancreatic cancer pill from Revolution Medicines.
View source ↗ - Newsseekingalpha.com·85d ago·Negative
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only …
View source ↗ - Newsdefenseworld.net·85d ago·Positive
Biotech Stocks To Watch Today – August 27th Moderna, Revolution Medicines, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop products or technologies based on biology, such as pharmaceuticals, vaccines, medical treatments, diagnostics, and genetic therapies. For investors, these stocks can offer significant growth potential but
View source ↗ - News (RSS)yahoo·86d ago·Neutral
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
View source ↗ - News (RSS)yahoo·86d ago·Neutral
Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
View source ↗ - News (Marketaux)gurufocus.com·86d ago·Positive
RVMD Maintained by UBS -- Price Target Raised to $265 On October 10, 2023, UBS maintained its [+188 characters]
View source ↗ - Newsmarketbeat.com·86d ago·Negative
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.
View source ↗ - News (RSS)fool·86d ago·Positive
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? The biotech's Rasonque is already available for prescription.
View source ↗ - Newsfool.com·86d ago·Neutral
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. It's a cancer medication with immense potential. In clinical testing, the pill was shown to double the survival rate of pancreatic cancer patients.
View source ↗ - News (RSS)seekingalpha·87d ago·Positive
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
View source ↗ - Newsseekingalpha.com·87d ago·Positive
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
View source ↗ - Newszacks.com·87d ago·Neutral
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
View source ↗ - News (Marketaux)gurufocus.com·88d ago·Neutral
Revolution Medicines (RVMD) Launches Rasonque Amid High Valuation and Mixed Insider Signals On August 26, 2026, Revolution [+307 characters]
View source ↗ - News (Marketaux)gurufocus.com·88d ago·Positive
RVMD Gains FDA Nod for Pancreatic Cancer Drug Amid High Price-to-Sales Valuation On August 26, 2026, Revolution [+319 characters]
View source ↗ - Newsglobenewswire.com·88d ago·Neutral
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer This release contains multimedia assets available for download here
View source ↗ - Newsbarrons.com·88d ago·Negative
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
View source ↗ - Newswsj.com·88d ago·Negative
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
View source ↗ - Newsreuters.com·88d ago·Negative
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
View source ↗ - News (RSS)yahoo·89d ago·Neutral
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
View source ↗ - Newsfool.com·89d ago·Neutral
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? Druckenmiller added roughly 26.5% to his position in Revolution Medicines in Q2. Analysts like the biotech stock, but the consensus price target reflects only modest upside potential.
View source ↗ - News (RSS)zerohedge·92d ago·Negative
President AOC's First Term President AOC's First Term Authored by Adam Sharp via DailyReckoning.com, The date is August 20th, 2032. We’re nearing the end of Alexandria Ocasio-Cortez’s first term as president. The wave of naive optimism that swept her into power has faded. But the damage is done. With a majority in both the Senate and House, the Democrats made big moves. First they eliminated the Senate filibuster. No more 60 votes needed to pass most legislation. Now a simple majority will do. T
View source ↗ - News (RSS)yahoo·94d ago·Negative
The AI-Powered Income Planning Revolution Has Arrived
View source ↗ - News (RSS)seekingalpha·94d ago·Neutral
Investing In The Building Blocks Of The Humanoid Revolution - Part 2 (The Brain)
View source ↗ - News (RSS)zerohedge·95d ago·Neutral
The DSA's War On Wealth The DSA's War On Wealth Authored by James Rickards via The Daily Reckoning, Communism is on the rise in the United States and has now entered otherwise mainstream Democratic Party politics. The Democratic Socialists of America (DSA) is on track to increase the number of its members in Congress from two to at least six in January, possibly more. That's not including Sen. Bernie Sanders, who calls himself a democratic socialist. A DSA member named Francesca Hong just came w
View source ↗ - News (RSS)investing·97d ago·Neutral
Revolution Medicines stock hits all-time high at 208.77 USD
View source ↗ - News (RSS)yahoo·99d ago·Neutral
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
View source ↗ - Newsbusinesswire.com·104d ago·Negative
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinica
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-1.15 per share
Typical surprise -15.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-1.90 vs $-2.35beat
- Wed, Aug 5$-3.06 vs $-2.04miss
- Wed, May 6$-2.29 vs $-1.84miss
- Wed, Feb 25$-1.86 vs $-1.58miss
- Wed, Nov 5$-1.61 vs $-1.42miss
- Wed, Aug 6$-1.31 vs $-1.14miss
Estimates and results for RVMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RVMD officers and directors.
- Bought
- —
- Sold
- $59.9m
0 trades
73 trades
- Kelsey Stephen Michaelsold
- Kelsey Stephen Michaelsold
- Kelsey Stephen Michaelsold
- Kelsey Stephen Michaelsold
- Kelsey Stephen Michaelsold
- Kelsey Stephen Michaelsold
- Anders Jacksold
- Anders Jacksold
27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RVMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
